120 related articles for article (PubMed ID: 28639200)
1. Treatment of Liver Cancer by C/EBPA saRNA.
Zhao X; Voutila J; Ghobrial S; Habib NA; Reebye V
Adv Exp Med Biol; 2017; 983():189-194. PubMed ID: 28639200
[TBL] [Abstract][Full Text] [Related]
2. C/EBPα Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/β-Catenin Signaling Mediated EMT.
Huan H; Wen X; Chen X; Wu L; Liu W; Habib NA; Bie P; Xia F
PLoS One; 2016; 11(4):e0153117. PubMed ID: 27050434
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma.
Zhao X; Reebye V; Hitchen P; Fan J; Jiang H; Sætrom P; Rossi J; Habib NA; Huang KW
Oncogene; 2019 May; 38(18):3446-3457. PubMed ID: 30643190
[TBL] [Abstract][Full Text] [Related]
4. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.
Reebye V; Sætrom P; Mintz PJ; Huang KW; Swiderski P; Peng L; Liu C; Liu X; Lindkaer-Jensen S; Zacharoulis D; Kostomitsopoulos N; Kasahara N; Nicholls JP; Jiao LR; Pai M; Spalding DR; Mizandari M; Chikovani T; Emara MM; Haoudi A; Tomalia DA; Rossi JJ; Habib NA
Hepatology; 2014 Jan; 59(1):216-27. PubMed ID: 23929703
[TBL] [Abstract][Full Text] [Related]
5. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.
Setten RL; Lightfoot HL; Habib NA; Rossi JJ
Curr Pharm Biotechnol; 2018; 19(8):611-621. PubMed ID: 29886828
[TBL] [Abstract][Full Text] [Related]
6. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
Voutila J; Reebye V; Roberts TC; Protopapa P; Andrikakou P; Blakey DC; Habib R; Huber H; Saetrom P; Rossi JJ; Habib NA
Mol Ther; 2017 Dec; 25(12):2705-2714. PubMed ID: 28882451
[TBL] [Abstract][Full Text] [Related]
7. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Reebye V; Huang KW; Lin V; Jarvis S; Cutilas P; Dorman S; Ciriello S; Andrikakou P; Voutila J; Saetrom P; Mintz PJ; Reccia I; Rossi JJ; Huber H; Habib R; Kostomitsopoulos N; Blakey DC; Habib NA
Oncogene; 2018 Jun; 37(24):3216-3228. PubMed ID: 29511346
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
[TBL] [Abstract][Full Text] [Related]
9. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.
Yoon S; Huang KW; Reebye V; Mintz P; Tien YW; Lai HS; Sætrom P; Reccia I; Swiderski P; Armstrong B; Jozwiak A; Spalding D; Jiao L; Habib N; Rossi JJ
Mol Ther; 2016 Jun; 24(6):1106-1116. PubMed ID: 26983359
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Pancreatic Cancer by Aptamer Conjugated C/EBPα-saRNA.
Yoon S; Rossi JJ
Adv Exp Med Biol; 2017; 983():173-188. PubMed ID: 28639199
[TBL] [Abstract][Full Text] [Related]
11. C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades.
Shi YC; Zhao H; Yin C; Zeng X; Zhang Q; Xu WP; Wei J; Chen F; Xie WF
Dig Liver Dis; 2013 Oct; 45(10):844-51. PubMed ID: 23816696
[TBL] [Abstract][Full Text] [Related]
12. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.
Zeng C; Wang R; Li D; Lin XJ; Wei QK; Yuan Y; Wang Q; Chen W; Zhuang SM
Hepatology; 2010 Nov; 52(5):1702-12. PubMed ID: 21038412
[TBL] [Abstract][Full Text] [Related]
13. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade.
Datta J; Majumder S; Kutay H; Motiwala T; Frankel W; Costa R; Cha HC; MacDougald OA; Jacob ST; Ghoshal K
Cancer Res; 2007 Mar; 67(6):2736-46. PubMed ID: 17363595
[TBL] [Abstract][Full Text] [Related]
14. Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC.
Yoon S; Huang KW; Andrikakou P; Vasconcelos D; Swiderski P; Reebye V; Sodergren M; Habib N; Rossi JJ
Mol Ther Nucleic Acids; 2019 Dec; 18():142-154. PubMed ID: 31546149
[TBL] [Abstract][Full Text] [Related]
15. CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma.
Tan EH; Hooi SC; Laban M; Wong E; Ponniah S; Wee A; Wang ND
Cancer Res; 2005 Nov; 65(22):10330-7. PubMed ID: 16288022
[TBL] [Abstract][Full Text] [Related]
16. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
18. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
19. CCAAT-enhancer binding protein-α (C/EBPα) and hepatocyte nuclear factor 4α (HNF4α) regulate expression of the human fructose-1,6-bisphosphatase 1 (FBP1) gene in human hepatocellular carcinoma HepG2 cells.
Wattanavanitchakorn S; Rojvirat P; Chavalit T; MacDonald MJ; Jitrapakdee S
PLoS One; 2018; 13(3):e0194252. PubMed ID: 29566023
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of the CCAAT/enhancer binding protein alpha gene involved in hepatocyte proliferation in human hepatocellular carcinomas.
Tomizawa M; Wang YQ; Ebara M; Saisho H; Watanabe K; Nakagawara A; Tagawa M
Int J Mol Med; 2002 Jun; 9(6):597-600. PubMed ID: 12011976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
